PRX019 — Clinical data readout
2026
In addition, we are conducting a Phase 1 clinical trial for PRX019 in collaboration with Bristol Myers Squibb with expected completion in 2026.Source filing
PRTA biotech catalysts & pipeline
PROTHENA CORP PUBLIC LTD CO · Data as of 2026-10-25
Upcoming catalysts
coramitug (formerly PRX004) — Clinical data readout
2027
Novo Nordisk initiated an open-label study to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)Source filing
moponetug — Clinical data readout
2027
Bristol Myers Squibb is conducting a Phase 2 TargetTau-1 clinical trial evaluating BMS-986446 in Alzheimer's disease with completion expected in 2027 and a Phase 1 clinical trial evaluating BMS-986446 in a potential subcutaneous formulation with completion expected in the second half of 2025.Source filing
coramitug (formerly PRX004) — Clinical data readout
2029
Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)Source filing
prasinezumab — Clinical data readout
2029
Roche is evaluating prasinezumab in the ongoing Phase 3 PARAISO clinical trial in ~900 participants with early-stage Parkinson's disease; primary completion expected in 2029 (NCT07174310)Source filing